Adma Biologics Income Statement (2011-2026) | ADMA

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Jun2026
Revenue & cost
Revenue (Quarter)	17.83M	20.68M	55.00M	29.10M	75.00M	41.09M	49.98M	56.91M	60.12M	110.00M	73.90M	81.88M	107.19M	119.84M	117.55M	114.80M	121.98M	134.22M	139.16M	124.39M
Cost of Revenue (Quarter)	2.80M	3.15M	-44.61M	25.44M	26.14M	4.86M	35.80M	1.78M	0.70M	0.47M	165.69M	1.00M	0.94M	60.18M	203.93M	1.29M	54.76M	58.60M	-162.22M	38.12M
Gross Profit (Quarter)	-1.00M	0.39M	3.51M	3.66M	7.77M	9.66M	14.18M	16.51M	16.69M	24.65M	31.09M	39.11M	57.45M	59.66M	63.33M	61.10M	67.23M	75.63M	88.82M	86.28M
Operating items
Amortization - Intangibles (Quarter)	0.20M	0.20M	0.20M	0.20M	0.20M	0.20M	0.20M	0.18M	0.20M	0.20M	0.22M	0.19M	0.14M	0.03M	0.03M	0.03M	0.03M	0.04M	0.05M	0.06M
Research & Development (Quarter)	1.16M	0.77M	0.73M	0.62M	0.87M	1.04M	1.07M	0.85M	1.40M	0.60M	0.45M	0.45M	0.56M	0.41M	0.39M	0.83M	1.03M	1.53M	1.38M	6.01M
Selling, General & Administrative (Quarter)	10.44M	10.73M	11.70M	13.70M	11.97M	12.89M	13.89M	14.51M	14.25M	14.73M	15.54M	15.64M	16.61M	18.56M	23.32M	24.08M	22.21M	21.78M	23.51M	26.74M
Other Operating Expenses (Quarter)	2.98M	3.33M	4.28M	4.15M	4.10M	5.04M	5.27M	1.96M	1.51M	0.65M	0.87M	1.20M	1.08M	1.05M	1.30M	1.31M	1.18M	1.31M	1.18M	1.08M
Operating Expenses (Quarter)	14.58M	14.82M	16.70M	18.48M	16.94M	18.97M	20.24M	17.33M	17.16M	15.97M	16.85M	17.29M	18.25M	20.02M	25.01M	26.22M	24.43M	24.61M	26.07M	33.83M
Operating Income (Quarter)	-15.58M	-14.44M	-13.19M	-14.82M	-9.17M	-9.32M	-6.06M	-0.81M	-0.47M	8.69M	14.23M	21.82M	39.20M	39.64M	38.32M	34.88M	42.80M	51.01M	62.75M	52.45M
EBIT (Quarter)	-15.58M	-14.44M	-13.19M	-14.82M	-9.17M	-9.32M	-6.06M	-0.81M	-0.47M	8.69M	14.23M	21.82M	39.20M	39.64M	38.32M	34.88M	42.80M	51.01M	62.75M	52.45M
Non-operating items
Interest & Investment Income (Quarter)	0.01M	0.00M	0.00M	0.03M	0.00M	0.01M	0.00M	0.17M	0.41M	0.42M	0.61M	0.38M	0.45M	0.67M	0.60M	0.61M	0.40M	0.38M	0.49M	1.24M
Other Non Operating Income (Quarter)		0.02M	-0.25M	-0.17M	-0.02M	-0.01M	-0.44M	-0.03M	-0.01M	-0.14M	-0.10M	-0.04M	-0.02M	-0.06M	-0.09M	-0.06M	-1.16M	-0.02M	2.08M	-0.02M
Non Operating Income (Quarter)	-3.32M	-3.28M	-3.46M	-3.52M	-4.59M	-5.58M	-6.17M	-5.98M	-5.90M	-6.12M	-31.88M	-3.42M	-3.35M	-2.89M	-3.61M	-1.43M	-2.70M	-3.50M	-1.16M	-2.21M
Net income details
EBT (Quarter)	-18.82M	-17.73M	-13.49M	-18.17M	-13.75M	-14.89M	-11.79M	-6.79M	-6.37M	2.56M	10.59M	18.40M	35.85M	36.75M	34.71M	33.45M	40.10M	47.52M	-121.06M	50.24M
Tax Provisions (Quarter)												0.59M	3.79M	0.84M	-15.15M	6.55M	5.88M	11.09M	12.22M	12.41M
Profit After Tax (Quarter)	-18.91M	-17.71M	-16.65M	-25.01M	-13.76M	-14.90M	-12.23M	-6.79M	-6.37M	2.56M	-17.64M	17.81M	32.06M	35.91M	111.90M	26.90M	34.22M	36.43M	49.38M	37.82M
Income from Continuing Operations (Quarter)	-18.82M	-17.73M	-13.49M	-18.17M	-13.75M	-14.89M	-11.79M	-6.79M	-6.37M	2.56M	10.59M	17.81M	32.06M	35.91M	49.87M	26.90M	34.22M	36.43M	-133.28M	37.82M
Consolidated Net Income (Quarter)	-18.82M	-17.73M	-13.49M	-18.17M	-13.75M	-14.89M	-11.79M	-6.79M	-6.37M	2.56M	10.59M	17.81M	32.06M	35.91M	49.87M	26.90M	34.22M	36.43M	-133.28M	37.82M
Income towards Parent Company (Quarter)	-18.82M	-17.73M	-13.49M	-18.17M	-13.75M	-14.89M	-11.79M	-6.79M	-6.37M	2.56M	10.59M	17.81M	32.06M	35.91M	49.87M	26.90M	34.22M	36.43M	-133.28M	37.82M
Net Income towards Common Stockholders (Quarter)	-18.82M	-17.73M	-13.49M	-18.17M	-13.75M	-14.89M	-11.79M	-6.79M	-6.37M	2.56M	10.59M	17.81M	32.06M	35.91M	49.87M	26.90M	34.22M	36.43M	-133.28M	37.82M
Additional items
EPS (Basic) (Quarter)	-0.15	-0.13	-0.10	-0.09	-0.07	-0.08	-0.06	-0.03	-0.03	0.01	0.05	0.08	0.14	0.15	0.21	0.11	0.14	0.15	-0.56	0.17
EPS (Diluted) (Quarter)	-0.15	-0.13	-0.10	-0.09	-0.07	-0.08	-0.06	-0.03	-0.03	0.01	0.05	0.08	0.13	0.15	0.20	0.11	0.14	0.15	-0.54	0.16
Shares Outstanding (Quarter)	127.42M	133.77M	139.58M	195.87M	196.35M	196.38M	197.87M	221.92M	222.68M	225.28M	223.98M	228.87M	232.42M	234.57M	233.08M	237.78M	241.49M	238.60M	238.30M	228.23M
Shares Outstanding (Diluted) (Quarter)	127.42M	133.77M	139.58M	195.87M	196.35M	196.38M	197.87M	221.92M	222.68M	233.76M	223.98M	236.41M	242.17M	244.80M	243.34M	244.68M	248.61M	244.66M	244.90M	230.34M
Shares Outstanding (Entity) (Quarter)	131.87M	138.31M	139.58M	196.35M	196.36M	196.78M	221.82M	222.26M	224.53M	225.96M	226.06M	231.77M	233.03M	236.38M	236.62M	238.53M	239.38M	239.66M	239.79M	241.09M
EBITDA (Quarter)	-15.58M	-14.44M	-13.19M	-14.82M	-9.17M	-9.32M	-6.06M	-0.81M	-0.47M	8.69M	14.23M	21.82M	39.20M	39.64M	38.32M	34.88M	42.80M	51.01M	62.75M	52.45M
Interest Expenses (Quarter)	3.25M	3.30M	0.30M	3.39M	4.57M	5.58M	5.74M	6.12M	6.30M	6.40M	6.21M	3.77M	3.78M	3.50M	8.87M	4.76M	15.40M	4.71M	-0.61M	9.86M
Tax Rate (Quarter)												3.23%	10.57%	2.29%	-43.66%	19.57%	14.66%	23.33%	-10.09%	24.71%

Research Tools

Datasets

Plans

Developers

Adma Biologics Income Statement (2011-2026) | ADMA

Research Tools

Datasets

Plans

Developers

Adma Biologics Income Statement (2011-2026) | ADMA

Create an account

Sign In

Reset Password